keyword
MENU ▼
Read by QxMD icon Read
search

Adrenocortical cancer

keyword
https://www.readbyqxmd.com/read/29045509/the-antibody-drug-conjugate-target-landscape-across-a-broad-range-of-tumour-types
#1
K L Moek, D J A de Groot, E G E de Vries, R S N Fehrmann
Background: Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Since ADC tumour cell targets do not have to be drivers of tumour growth, ADCs are potentially relevant for a wide range of tumours currently lacking clear oncogenic drivers. Therefore, we aimed to define the landscape of ADC targets in a broad range of tumours. Materials and methods: PubMed and ClinicalTrials...
September 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29029450/new-insights-in-the-clinical-and-translational-relevance-of-mir483-5p-in-adrenocortical-cancer
#2
Francesca Salvianti, Letizia Canu, Giada Poli, Roberta Armignacco, Cristian Scatena, Giulia Cantini, Alessandra Di Franco, Stefania Gelmini, Tonino Ercolino, Mario Pazzagli, Gabriella Nesi, Massimo Mannelli, Pamela Pinzani, Michaela Luconi
Adrenocortical cancer (ACC) is a rare aggressive malignancy. Recent ACC integrated genomics analysis contributed to redefine the risk groups on molecular basis, including tumor microRNAs (miRs), detectable also in the bloodstream. We developed a quantitative real-time (RT) assay for the measurement of miR483 and miR483-5p absolute levels in plasma samples. miR483/miR483-5p levels were evaluated in plasma samples of 27 patients with ACC before surgery and at follow-up. Statistically significant differences in miR483-5p and miR483 levels were found between stage 1/2 and stage 3/4 ACCs in pre-surgery and post-surgery samples...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29022106/minimally-invasive-adrenalectomy-for-adrenocortical-carcinoma-five-year-trends-and-predictors-of-conversion
#3
Natalie A Calcatera, Chi Hsiung-Wang, Nicholas R Suss, David J Winchester, Tricia A Moo-Young, Richard A Prinz
BACKGROUND: Adrenocortical carcinoma (ACC) is rare but often fatal. Surgery offers the only chance of cure. As minimally invasive (MI) procedures for cancer become common, their role for ACC is still debated. We reviewed usage of MI approaches for ACC over time and risk factors for conversion using a large national database. METHODS: ACC patients with localized disease were identified in the National Cancer Data Base from 2010 to 2014. A retrospective review examined trends in the surgical approach over time...
October 11, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28973495/identification-of-mutations-in-cell-free-circulating-tumor-dna-in-adrenocortical-carcinoma-a-case-series
#4
Sara G Creemers, Esther Korpershoek, Peggy N Atmodimedjo, Winand N M Dinjens, Peter M van Koetsveld, Richard A Feelders, Leo J Hofland
Context: The disease course of adrenocortical carcinoma (ACC) patients is heterogeneous. A marker for prognosis and treatment response would facilitate choices on diagnosis and therapy. In other cancer types, circulating cell-free tumor DNA (ctDNA) predicted tumor dynamics. Case descriptions: This pilot study included six patients. Next-generation sequencing (NGS) showed mutations in 3 ACCs. From these patients, blood was drawn before (1-2 weeks) and after surgery, from which cell-free circulating DNA (cfDNA) was isolated...
June 30, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28972963/a-phase-1-study-of-arq-087-an-oral-pan-fgfr-inhibitor-in-patients-with-advanced-solid-tumours
#5
K P Papadopoulos, B F El-Rayes, A W Tolcher, A Patnaik, D W Rasco, R D Harvey, P M LoRusso, J C Sachdev, G Abbadessa, R E Savage, T Hall, B Schwartz, Y Wang, J Kazakin, W L Shaib
BACKGROUND: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose (RP2D). METHODS: Patients with advanced solid tumours received ARQ 087 administered initially at 25 mg every other day and dose-escalated from 25 to 425 mg daily (QD) continuous dosing. FGF19, 21, 23, and serum phosphate were assessed as potential biomarkers of target engagement...
October 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28968749/omics-analysis-system-for-precision-oncology-oasispro-a-web-based-omics-analysis-tool-for-clinical-phenotype-prediction
#6
Kun-Hsing Yu, Michael R Fitzpatrick, Luke Pappas, Warren Chan, Jessica Kung, Michael Snyder
Summary: Precision oncology is an approach that accounts for individual differences to guide cancer management. Omics signatures have been shown to predict clinical traits for cancer patients. However, the vast amount of omics information poses an informatics challenge in systematically identifying patterns associated with health outcomes, and no general-purpose data-mining tool exists for physicians, medical researchers, and citizen scientists without significant training in programming and bioinformatics...
September 12, 2017: Bioinformatics
https://www.readbyqxmd.com/read/28954751/unilateral-adrenal-mass-as-the-sole-initial-manifestation-of-differentiated-thyroid-cancer
#7
Geethalakshmi Sampathkumar, Arun S Menon, Bindhu M R, Vasantha Nair
Unilateral adrenal metastases without disseminated disease has rarely been reported in differentiated thyroid carcinoma (DTC). A 72-year-old female presented with vague abdominal discomfort and loss of appetite of 2 months duration. She had undergone left hemithyroidectomy for a benign thyroid nodule 18 years ago. A contrast CT of the abdomen showed a large left adrenal mass measuring 11×9 cm, suspicious of adrenocortical carcinoma. Hormonal evaluation was in keeping with a non-functional tumour. The patient underwent left adrenalectomy, histopathology of which revealed metastatic well-differentiated thyroid carcinoma...
September 27, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28943972/small-non-coding-rna-abundance-in-adrenocortical-carcinoma-a-footprint-of-a-rare-cancer
#8
Srinivas V Koduru, Ashley N Leberfinger, Dino J Ravnic
BACKGROUND: Adrenocortical carcinoma (ACC) is a relatively rare, but aggressive type of cancer, which affects both children and adults. OBJECTIVE: Small non-coding RNAs (sncRNAs) play important roles and may serve as biomarkers for disease diagnosis, prognosis and treatment. METHODS: In our study, we sought to identify sncRNAs associated with malignant adrenal tumors. We obtained publicly available, small RNA sequencing data derived from 45 ACC and 30 benign tumors arising from the cortex of the adrenal gland, adrenocortical adenomas (ACA), and compared their sncRNA expression profiles...
2017: Journal of Genomics
https://www.readbyqxmd.com/read/28895102/the-impact-of-nodal-dissection-on-staging-in-adrenocortical-carcinoma
#9
Suraj Panjwani, Maureen D Moore, Katherine D Gray, Brendan M Finnerty, Toni Beninato, Laurent Brunaud, Thomas J Fahey, Rasa Zarnegar
BACKGROUND: The role of lymphadenectomy in adrenocortical carcinoma (ACC) is controversial, and formal lymph node (LN) dissection is not routine. We sought to determine the minimum number of LNs that must be examined to accurately identify a patient as node negative. METHODS: The National Cancer Database was used to identify patients diagnosed with ACC from 2004 to 2013 who underwent surgical resection. Patients with distant metastases, multivisceral resection, or missing surgical or lymphadenectomy data were excluded...
September 11, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28893836/immunotherapy-against-endocrine-malignancies-immune-checkpoint-inhibitors-lead-the-way
#10
Lucas Leite Cunha, Marjory Alana Marcello, Vinicius Rocha-Santos, Laura Sterian Ward
Immune checkpoint inhibitors are agents that act by inhibiting the mechanisms of immune escape displayed by various cancers. The success of immune checkpoint inhibitors against several tumors has promoted a new treatment strategy in clinical oncology, and this has encouraged physicians to increase the number of patients who receive the immune checkpoint therapy. In the present article, we review the main concepts regarding immune checkpoint mechanisms and how cancer disrupts them to undergo immune escape. In addition, we describe the most essential concepts related to immune checkpoint inhibitors...
September 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28888979/resveratrol-piceatannol-and-analogs-inhibit-activation-of-both-wild-type-and-t877a-mutant-androgen-receptor
#11
Johan Lundqvist, Corrado Tringali, Agneta Oskarsson
Prostate cancer growth and progression is mainly dependent on androgens and many current prostate cancer treatment options target the synthesis or function of androgens. We have previously reported that resveratrol and synthetic analogs of resveratrol with a higher bioavailability inhibit the synthesis of androgens in human adrenocortical H295R cells. Now we have studied the antiandrogenic properties of resveratrol, piceatannol and analogs in two different prostate cell lines; LNCaP and RWPE. LNCaP carry a T877A mutation in the androgen receptor while RWPE has a wild-type androgen receptor...
September 6, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28887710/increased-mortality-in-patients-with-adrenal-incidentalomas-and-autonomous-cortisol-secretion-a-13-year-retrospective-study-from-one-center
#12
Jekaterina Patrova, Magnus Kjellman, Hans Wahrenberg, Henrik Falhammar
PURPOSE: To compare long-term outcomes in patients with adrenal incidentalomas (AIs) with the response to a 1 mg overnight dexamethasone suppression test (DST). METHODS: Consecutive patients with "non-functional" AIs (n = 365) were examined. Patients with overt hormone excess, adrenocortical cancer and known malignancy had been excluded. Patients were classified to normal cortisol secretion group (n = 204, DST ≤ 50 nmol/l), possible autonomous cortisol secretion group (n = 128, DST 51-138 nmol/l) and autonomous cortisol secretion group (n = 33, DST ≥ 138 nmol/l)...
September 8, 2017: Endocrine
https://www.readbyqxmd.com/read/28887601/is-there-a-role-for-epithelial-mesenchymal-transition-in-adrenocortical-tumors
#13
Daniel Bulzico, Paulo Antônio Silvestre de Faria, Camila Bravo Maia, Marcela Pessoa de Paula, Davi Coe Torres, Gerson Moura Ferreira, Bruno Ricardo Barreto Pires, Rocio Hassan, Eliana Abdelhay, Mario Vaisman, Leonardo Vieira Neto
PURPOSE: Epithelial-mesenchymal transition (EMT) is a biological dynamic process by which epithelial cells lose their epithelial phenotype and acquire mesenchymal invasive and migratory characteristics. This has been postulated as an essential step during cancer progression and metastasis. Although this is well described in other tumors, the role of EMT in adrenocortical tumors (ACT) has yet to be addressed. METHODS: The aim of this study was to evaluate the expression of EMT markers e-cadherin, vimentin, and fibronectin, along with EMT-transcription factors (EMT-TFs), TWIST1, SIP1, and SNAIL in 24 adrenocortical carcinoma (ACC), 19 adrenocortical adenomas (ACA), 27 childhood-onset adrenocortical tumors (CAT), and 12 normal adrenal glands...
September 8, 2017: Endocrine
https://www.readbyqxmd.com/read/28881628/establishment-of-a-mouse-xenograft-model-of-metastatic-adrenocortical-carcinoma
#14
Aurélie Morin, Carmen Ruggiero, Estelle Robidel, Mabrouka Doghman-Bouguerra, Atze T Das, Rémy Castellano, Emmanuelle Josselin, Judith Favier, Enzo Lalli
Adrenocortical carcinoma is a rare neoplasm with a poor prognosis. Very important advances have been made in the identification of the genetic determinants of adrenocortical carcinoma pathogenesis but our understanding is still limited about the mechanisms that determine cancer spread and metastasis. One major problem hindering preclinical experimentation for new therapies for adrenocortical carcinoma is represented by the lack of suitable animal models for metastatic disease. With the aim to overcome these limitations, in this study we tested several protocols in order to establish a mouse xenograft model of metastatic adrenocortical carcinoma...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28880439/complete-response-in-a-patient-with-stage-iv-adrenocortical-carcinoma-treated-with-adjuvant-trans-catheter-arterial-chemo-embolization-tace
#15
Eugene Wong, Sarah Jacques, Michael Bennett, Vineet Gorolay, Adrian Lee, Stephen Clarke
Adrenocortical carcinoma is a rare cancer, with estimate population incidence of 0.7-2.0 cases per 1 million each year. It also carries poor prognosis with estimated 5-year survival of less than 15% of those with metastatic disease and has a poor response to cytotoxic treatment. A randomized controlled trial published in 2012 by Fassnacht et al. demonstrated improved progression-free survival with first-line etoposide-doxirubicin-cisplatin-mitotane (EDP-M) compared to first-line streptozocin-mitotane in patients with stage III-IV disease...
September 6, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28874901/adrenocortical-carcinoma-patterns-of-care-and-role-of-adjuvant-radiation-therapy-a-population-based-study-and-review-of-the-literature
#16
REVIEW
S Atallah, H Al-Assaf, Y Xu, S El-Sayed
PURPOSE: We reviewed the experience of a tertiary cancer centre in the management of adrenocortical carcinoma (acc) treated over 40 years. We also searched the literature for guidelines related to the treatment of acc and for evidence for adjuvant radiation therapy (rt). METHODS: In a retrospective chart review, acc patients treated between January 1974 and December 2013 were identified, and patient demographics and tumour characteristics were extracted. Outcomes data, including dates and sites of failure, vital status, and cause of death, were collected...
August 2017: Current Oncology
https://www.readbyqxmd.com/read/28864397/adrenocortical-tumors-associated-with-the-tp53-p-r337h-germline-mutation-can-be-identified-during-child-care-consultations
#17
Maria J Mastellaro, Raul C Ribeiro, Antônio G Oliveira-Filho, Ana L Seidinger, Izilda A Cardinalli, Eliana C M Miranda, Simone S Aguiar, Silvia R Brandalise, José A Yunes, Antônio A Barros-Filho
OBJECTIVE: To evaluate the clinical features associated with adrenocortical hormone overexpression and familial cancer profiling as potential markers for early detection of adrenocortical tumors in children from South and Southeast Brazil. METHODS: The clinical manifestations and anthropometric measurements of 103 children diagnosed with adrenocortical tumors were analyzed. RESULTS: Between 1982 and 2011, 69 girls and 34 boys diagnosed with adrenocortical tumors were followed-up for a median time of 9...
August 30, 2017: Jornal de Pediatria
https://www.readbyqxmd.com/read/28844117/well-differentiated-thyroid-cancer-neovasculature-expresses-prostate-specific-membrane-antigen-a-possible-novel-therapeutic-target
#18
Maureen Moore, Suraj Panjwani, Rashmi Mathew, Michael Crowley, Yi-Fang Liu, Anna Aronova, Brendan Finnerty, Rasa Zarnegar, Thomas J Fahey, Theresa Scognamiglio
Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein receptor, is highly expressed in prostate cancer and in the tumor neovasculature of colon, breast, and adrenocortical tumors. Here, we analyzed PSMA expression in the neovasculature of various thyroid cancer subtypes and assessed whether PSMA expression is correlated with aggressive behavior. From a prospectively maintained database, we evaluated 91 samples from 68 patients, including 37 primary differentiated thyroid cancers (DTCs) [11 classic papillary (cPTC), 9 follicular-variant (FvPTC), 11 follicular (FTC), 6 radioactive iodine-refractory (RAIR)], 5 anaplastic (ATC) carcinomas, 9 distant and 12 lymph node metastases, 21 benign thyroid nodules, and 7 normal thyroid specimens...
August 26, 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/28809444/circannual-variation-of-mitotane-and-its-metabolites-plasma-levels-in-patients-with-adrenocortical-carcinoma
#19
Jessica Cusato, Silvia De Francia, Sarah Allegra, Simona Carrella, Elisa Pirro, Francesca Maria Piccione, Francesca De Martino, Anna Ferrero, Fulvia Claudia Daffara, Massimo Terzolo, Alfredo Berruti, Francesco Di Carlo, Marco Tampellini, Antonio D'Avolio
OBJECTIVES: Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate). Mitotane and metabolites are lipophilic agents; thus, they tend to accumulate into adipose tissues (white and brown), which change their prevalence seasonally. Aim of the work was to evaluate mitotane and metabolites plasma levels variation over the year, in adrenocortical cancer patients treated with Lysodren(®) for at least 6 months...
August 15, 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28801373/metformin-and-melatonin-in-adrenocortical-carcinoma-morphoproteomics-and-biomedical-analytics-provide-proof-of-concept-in-a-case-study
#20
Robert E Brown, Jamie Buryanek, Mary F McGuire
Metformin has been proposed as a novel anti-cancer drug for adrenocortical carcinoma (ACC) based upon Poli's recent preclinical studies that 1. "in vitro" metformin modulates the ACC cell model H295R and 2. "in vivo" metformin inhibits tumor growth in a xenograft model as confirmed by a significant reduction of Ki67 [1]. Here we report on our prior clinical case study that provides proof of concept for Poli's studies. We were requested to perform morphoproteomic analysis to further define the biology of, and raise targeted therapeutic options, for a case of post-treatment and chemoresistant ACC metastatic to the liver and the lung...
August 2017: Annals of Clinical and Laboratory Science
keyword
keyword
53561
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"